Abingworth LLP Hille Vax, Inc. Call Options Transaction History
Abingworth LLP
- $301 Million
- Q4 2022
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding HLVX
# of Institutions
97Shares Held
40.9MCall Options Held
0Put Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.6MShares$20.3 Million9.05% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4MShares$7.65 Million1.22% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.48MShares$6.65 Million0.03% of portfolio
-
Black Rock Inc. New York, NY2.09MShares$3.99 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA1.99MShares$3.8 Million0.01% of portfolio
About HilleVax, Inc.
- Ticker HLVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,427,200
- Market Cap $63.8M
- Description
- HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.